Total submissions: 3
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Prevention |
RCV003402153 | SCV004111867 | uncertain significance | NTHL1-related disorder | 2023-02-23 | criteria provided, single submitter | clinical testing | The NTHL1 c.602G>T variant is predicted to result in the amino acid substitution p.Gly201Val. To our knowledge, this variant has not been reported in the literature or in a large population database (http://gnomad.broadinstitute.org), indicating this variant is rare. At this time, the clinical significance of this variant is uncertain due to the absence of conclusive functional and genetic evidence. |
Ambry Genetics | RCV004362812 | SCV005019768 | uncertain significance | Hereditary cancer-predisposing syndrome | 2023-01-14 | criteria provided, single submitter | clinical testing | The p.G201V variant (also known as c.602G>T), located in coding exon 4 of the NTHL1 gene, results from a G to T substitution at nucleotide position 602. The glycine at codon 201 is replaced by valine, an amino acid with dissimilar properties. This amino acid position is conserved. In addition, this alteration is predicted to be tolerated by in silico analysis. Since supporting evidence is limited at this time, the clinical significance of this alteration remains unclear. |
Baylor Genetics | RCV004572968 | SCV005053734 | uncertain significance | Familial adenomatous polyposis 3 | 2024-02-06 | criteria provided, single submitter | clinical testing |